GlassScriptPhysician profile
Jerome H Waller
NPI 1043262868
$5,455.87
in general payments reported to CMS, 2019-2025
31 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $614 · 2021: $879 · 2022: $828 · 2023: $1,072 · 2024: $889 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $863.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $805.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $682.03 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $680.92 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.32 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Abbvie INC. | $287.45 | 2021-2025 | Dalvance, Qulipta, Ubrelvy |
| Pfizer INC. | $235.33 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $193.05 | 2019-2022 | |
| Amgen INC. | $184.54 | 2019-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $152.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $144.68 | 2021-2024 | Freestyle Libre 2, Proclaim, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $123.62 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $100.61 | 2019-2023 | Spravato |
| Cranial Technologies, INC | $74.74 | 2022-2024 | Doc Band |
| Dexcom, INC. | $65.90 | 2020-2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.96 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $52.15 | 2022-2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $45.78 | 2023 | Quviviq |
| Eisai INC. | $37.30 | 2021-2023 | |
| Phadia US INC. | $33.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.39 | 2020-2021 | |
| Esperion Therapeutics, INC. | $27.96 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.50 | 2021-2023 | |
| Edwards Lifesciences Corporation | $24.37 | 2025 | Sapien 3 Ultra Resilia |
| Ultragenyx Pharmaceutical INC. | $23.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.06 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.28 | 2025 | Caplyta |
| Amarin Pharma, INC. | $18.98 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $14.20 | 2019 | |
| Merck Sharp & Dohme LLC | $13.57 | 2023 | Gardasil 9, M-M-R II, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Waller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.